Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the progression-free survival of patients with multiple myeloma treated with tandem cycles of high-dose melphalan followed by high-dose melphalan in combination with bortezomib with autologous HSC transplantation.
Michele Donato, MD
John Theurer Cancer Center at Hackensack University Medical Center
United States: Institutional Review Board
|John Theurer Cancer Center @ Hackensack University Medical Center||Hackensack, New Jersey 07601|